Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in Chronic Hypoparathyroidism
NCT00743782Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Aug 2008
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of teriparatide in hypoparathyroidism (2 arms), sponsored by National Institutes of Health. Primary endpoints: Mean Serum Calcium at 13 weeks and Mean Urine Calcium Excretion at 13 weeks. Started Aug 2008; status: completed.
02
Drugs
teriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT00743782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00743782.